There are a number of reasons why you may consider adding magnesium glycinate to your daily routine. But taking this ...

MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...

Explore how AI-powered wireless implants could replace opioids, using ultrasonic energy to block chronic pain signals without addiction risk.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.

In This Article, You'll Discover Understanding how NerveFreedom's unique formulation addresses multiple aspects of ner ...

The Swedish Brain Foundation (Hjärnfonden) is making its largest donation to date to Swedish brain research. This year, SEK ...

As people age, their risk of developing type 2 diabetes increases. In fact, age is one of the most important risk factors for ...

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from an existing customer in the United States. The customer is an experienced user of the Nexstim therapy ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

C7 neurotomy added to standard speech therapy enhances language recovery in patients with chronic post-stroke aphasia, a randomized trial suggests.

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...